-
Je něco špatně v tomto záznamu ?
Mutation in the immunodominant epitope of the HPV16 E7 oncoprotein as a mechanism of tumor escape
Michal Smahel, Pavla Tejklova, Jana Smahelova, Ingrid Polakova, Jana Mackova
Jazyk angličtina Země Německo
Grantová podpora
NR9246
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Zdroj
NLK
PubMed Central
od 1982
ProQuest Central
od 1997-01-01 do 2017-12-31
Medline Complete (EBSCOhost)
od 2000-04-01
Health & Medicine (ProQuest)
od 1997-01-01 do 2017-12-31
Public Health Database (ProQuest)
od 1997-01-01 do 2017-12-31
ROAD: Directory of Open Access Scholarly Resources
od 2002
- MeSH
- antigeny nádorové chemie MeSH
- bodová mutace MeSH
- epitopy chemie MeSH
- financování organizované MeSH
- H-2 antigeny chemie MeSH
- imunodominantní epitopy chemie MeSH
- imunoterapie metody MeSH
- lidé MeSH
- mutace MeSH
- myši inbrední C57BL MeSH
- myši MeSH
- nádory imunologie metabolismus terapie MeSH
- onkogenní proteiny virové genetika chemie MeSH
- onkogenní proteiny chemie MeSH
- Papillomavirus E7 - proteiny MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
Infection with high-risk types of human papillomavirus (HPV) can cause the development of malignant tumors. To study mechanisms responsible for immune escape of tumor cells infected with HPV16, we previously used mouse oncogenic TC-1 cells producing HPV16 E6 and E7 oncoproteins to derive TC-1 clones resistant to immunization against E7. We have found immunoresistance of the clones to correlate with the point mutation in the E7 oncogene, which resulted in the N53S substitution in the immunodominant epitope RAHYNIVTF (aa 49-57). Here, we have shown that this mutation reduced stabilization of H-2D(b) molecules on RMA-S cells and eliminated immunogenicity of E7. The resistance of TC-1 clones was E7-specific as immunization against E6 inhibited tumor growth. Transduction of the TC-1/F9 clone carrying the mutated epitope with the wild-type E7 gene restored susceptibility to immunization against E7. Our results suggest that mutagenesis of tumor antigens can lead to the escape of malignant cells and should be considered in the development and evaluation of cancer immunotherapy.
Citace poskytuje Crossref.org
- 000
- 02922naa 2200481 a 4500
- 001
- bmc11003685
- 003
- CZ-PrNML
- 005
- 20140723100256.0
- 008
- 110302s2008 gw e eng||
- 009
- AR
- 024 __
- $a 10.1007/s00262-007-0418-9 $2 doi
- 035 __
- $a (PubMed)17962940
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Šmahel, Michal $7 xx0060364 $u Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 245 10
- $a Mutation in the immunodominant epitope of the HPV16 E7 oncoprotein as a mechanism of tumor escape / $c Michal Smahel, Pavla Tejklova, Jana Smahelova, Ingrid Polakova, Jana Mackova
- 314 __
- $a Department of Experimental Virology, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic. smahel@uhkt.cz
- 520 9_
- $a Infection with high-risk types of human papillomavirus (HPV) can cause the development of malignant tumors. To study mechanisms responsible for immune escape of tumor cells infected with HPV16, we previously used mouse oncogenic TC-1 cells producing HPV16 E6 and E7 oncoproteins to derive TC-1 clones resistant to immunization against E7. We have found immunoresistance of the clones to correlate with the point mutation in the E7 oncogene, which resulted in the N53S substitution in the immunodominant epitope RAHYNIVTF (aa 49-57). Here, we have shown that this mutation reduced stabilization of H-2D(b) molecules on RMA-S cells and eliminated immunogenicity of E7. The resistance of TC-1 clones was E7-specific as immunization against E6 inhibited tumor growth. Transduction of the TC-1/F9 clone carrying the mutated epitope with the wild-type E7 gene restored susceptibility to immunization against E7. Our results suggest that mutagenesis of tumor antigens can lead to the escape of malignant cells and should be considered in the development and evaluation of cancer immunotherapy.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antigeny nádorové $x chemie $7 D000951
- 650 _2
- $a epitopy $x chemie $7 D000939
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a H-2 antigeny $x chemie $7 D006183
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunodominantní epitopy $x chemie $7 D016056
- 650 _2
- $a imunoterapie $x metody $7 D007167
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a nádory $x imunologie $x metabolismus $x terapie $7 D009369
- 650 _2
- $a onkogenní proteiny $x chemie $7 D015513
- 650 _2
- $a onkogenní proteiny virové $x genetika $x chemie $7 D009856
- 650 _2
- $a Papillomavirus E7 - proteiny $7 D050725
- 650 _2
- $a bodová mutace $7 D017354
- 650 _2
- $a financování organizované $7 D005381
- 700 1_
- $a Tejklová, Pavla $7 xx0128838 $u Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Šmahelová, Jana $7 xx0110565 $u Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Poláková, Ingrid $7 xx0139787 $u Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Macková, Jana $7 xx0062103 $u Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 773 0_
- $t Cancer Immunology, Immunotherapy $w MED00001041 $g Roč. 57, č. 6 (2008), s. 823-831 $x 0340-7004
- 910 __
- $a ABA008 $b x $y 7 $z 0
- 990 __
- $a 20110413121102 $b ABA008
- 991 __
- $a 20140723100605 $b ABA008
- 999 __
- $a ok $b bmc $g 831091 $s 695707
- BAS __
- $a 3
- BMC __
- $a 2008 $b 57 $c 6 $d 823-831 $i 0340-7004 $m Cancer immunology and immunotherapy $n Cancer Immunol Immunother $x MED00001041
- GRA __
- $a NR9246 $p MZ0
- LZP __
- $a 2011-3B/vtme